PDF Cover

Pacritinib Market

Pacritinib Market

The market for Pacritinib was estimated at $816 million in 2024; it is anticipated to increase to $1.23 billion by 2030, with projections indicating growth to around $1.74 billion by 2035.

Report ID:DS1802419
Author:Debadatta Patel - Senior Consultant
Published Date:June 2025
Datatree
Life Science
Pharmaceutical
Pacritinib
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Pacritinib Market Outlook

Revenue, 2024

$816M

Forecast, 2034

$1.62B

CAGR, 2024 - 2034

7.1%
The Pacritinib industry revenue is expected to be around $874.2 million in 2025 and expected to showcase growth with 7.1% CAGR between 2025 and 2034. Pacritinibs strong compound annual growth rate reflects its increasing popularity in the sector due to its main influencing factors. Thanks to its effectiveness in treating bone marrow disease and impressive therapeutic results it has become a prominent treatment option in the field. The focus on innovation driven approaches, an investment, in research and development and thorough examination of patient data contribute significantly to its market position.

Pacritinib is a medication known for its promise in addressing illnesses like myelofibrosis and various blood cancers. Additionally,. Pacritinibs consistent efficacy stands out because it remains effective for patients, with low platelet levels when compared to alternative treatments.

Pacritinib market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Pacritinib market is projected to grow from $816.2 million in 2024 to $1.62 billion in 2034. This represents a CAGR of 7.1%, reflecting rising demand across Myelofibrosis Treatment, Leukocytosis Management and Secondary Thrombocytopenia Therapy.
  • CTI Biopharma Corp, Baxter International Inc, Eli Lilly and Company are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Germany are the top markets within the Pacritinib market and are expected to observe the growth CAGR of 4.6% to 6.8% between 2024 and 2030.
  • Emerging markets including Brazil, India and South Africa are expected to observe highest growth with CAGR ranging between 8.2% to 9.8%.
  • Transition like Shift towards Targeted Therapies is expected to add $115 million to the Pacritinib market growth by 2030
  • The Pacritinib market is set to add $804 million between 2024 and 2034, with manufacturer targeting Research Institutions & Hospitals End-Users projected to gain a larger market share.
  • With Increasing prevalence of myelofibrosis, and Unmet medical needs in myelofibrosis therapeutics, Pacritinib market to expand 99% between 2024 and 2034.
pacritinib market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Pacritinib

The changing realm of drug delivery presents a promising future for Pacritinib treatment options. Cutting edge advancements like nanotechnology driven drug delivery and tailored medicine have the potential to enhance the effectiveness and safety of Pacritinib therapy ultimately boosting its standing, in the market.

Growth Opportunities in North America and Asia-Pacific

North America Outlook

North America, the United States represents a significant market for Pacritinib because of the high rates of myelofibrosis and related conditions in the region. There are favorable prospects here thanks to ongoing research and development activities and the involvement of major pharmaceutical companies. Competition, in this market is intense as leading companies are working together to speed up the approval of new drugs. Key factors in North America consist of a healthcare system​s​ and an increasing number of common diseases. Moreover​, the growing elderly population is more susceptible, to long term health conditions.

Asia-Pacific Outlook

The Asia Pacific region shows growth in the Pacritinib market thanks to increased awareness of chronic diseases and advancements in healthcare infrastructure development. Japan, China and India stand out as players in this region due to their growing pharmaceutical industries. Competition in the Asia Pacific market is intensifying as new entrants are making investments in product innovation and expansion tactics. Factors driving this trend include rising healthcare expenditures, enhanced patient knowledge and diagnostic facilities and a growing incidence of blood disorders such, as myelofibrosis. The expansion is also aided by the efforts of governments to enhance healthcare services.

Market Dynamics and Supply Chain

01

Driver: Increasing Prevalence of Myelofibrosis

Pacritinib is also mainly targeted towards addressing the growing instances of diseases like myelofibrosis that it is also tailored to treat. Studies indicate an uptick in the prevalence of this condition worldwide necessitating the demand for better and more tolerable treatment choices such, as Pacritinib which has also displayed considerable potential in advanced clinical trials.
In the realm of treatment for myelofibrosis lies a significant market opportunity due to the lack of effective solutions despite progress in medical research and technology advancements. The search for a cure continues to challenge scientists and healthcare professionals within this field creating a promising space for innovative therapies such, as Pacritinib that exhibit promise in enhancing both survival rates and the well being of individuals battling with this illness.
02

Restraint: Regulatory Hurdles

As a potential new medication in development process called Pacritinib encounters regulatory obstacles to overcome before it can be approved for public use. There are challenges from bodies like the Food and Drug Administration that closely monitor its progress and have the authority to pause or stop its advancement depending on the outcomes of clinical trials. These legal hurdles could impact how Pacritinib is perceived in the market and influence its reception and utilization, by consumers.
03

Opportunity: Penetrating Untapped Markets and Strategic Collaborations to Enhance Research & Development

As an innovative treatment option on the market today Pacritinib shows promising potential to break through into previously unexplored territories. Areas experiencing a rise in diseases such as myelofibrosis and variouss of cancer which Pacritinib is known to address are seen as opportunities, for growth. Expanding into these regions could result in usage rates ultimately boosting Pacritinibs presence in both the pharmaceutical and healthcare industries.
Within the pharmaceutical sector collaborations, promotions and mergers can serve as tools, for driving growth and success for Pacritinib. Combining resources to enhance research and development initiatives could lead to the identification of therapeutic applications or enhancements that improve Pacritinibs effectiveness and minimize potential side effects.
04

Challenge: Competition from Established Drugs

Significant difficulties in the Pacritinib market arise from competing with known medications already available in the market space. Whenever new treatments emerge they are typically judged against existing therapies based on their effectiveness impact on patients health outcomes and potential side effects. If Pacritinib fails to show an enhancement, in these aspects it might face challenges in gaining a significant share of the market thus constraining its demand and growth potential.

Supply Chain Landscape

1
Raw Material Acquisition

BASF SE

Dow Inc.

Ashland Global Holdings

2
Drug Synthesis & Scale-Up

Johnson & Johnson

Pfizer Inc

3
Development & Manufacturing

CTI BioPharma Corp

Incyte Corporation

4
Distribution & End Market Delivery

Walgreens Boots Alliance

CVS Health Corporation

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Pacritinib in Myelofibrosis Treatment, Leukocytosis Management & Secondary Thrombocytopenia Therapy

Myelofibrosis Treatment

In the field Pacritinib is widely utilized as a strong inhibitor to combat myelofibrosis, a rare form of bone marrow cancer that affects cell growth and development by blocking Janu Associated Kinases enzymes activity effectively especially in individuals with low platelet levels; pharmaceutical leaders, like CTI Biopharma have notably profited from its enhanced efficacy and reduced adverse reactions compared to alternative therapies.

Secondary Thrombocytopenia Therapy

Pacritinib is also used effectively to treat thrombocytopenia by acting as a small molecule inhibitor that targets JAK2 and FLT3 genes specifically to boost platelet levels in patients. This diverse therapy approach extends Pacritinibs reach beyond myelofibrosis treatment. Gives companies like Gilead Sciences a competitive advantage, in the market.

Leukocytosis Management

Pacritinib is commonly utilized for controlling white blood cell counts in individuals who do not only respond well to other treatment options. Its primary use, in this context involves its function as a blocker of JAK and FLT proteins.

Recent Developments

September 2024

Pacritinib has been given the light by the European Medicines Agency to be used in treating myelofibrosis—a noteworthy achievement, for CTl BioPharma Corp.

July 2024

Inceptua Medicines Access teamed up with CT BioPharma to offer approved access to Pacritinib, in Europe and the Middle East.

March 2024

CTi BioPharma Corp announced outcomes from a Phase 3 study of Pacritinib focusing on severe thromboytopenia.

Pacritinib is making an impact in the field of blood related cancers and is becoming more prominent in treatment plans due to increased interest driven by rising cases of chronic illnesses and advancements, in medical treatments.

Impact of Industry Transitions on the Pacritinib Market

As a core segment of the Pharmaceutical industry, the Pacritinib market develops in line with broader industry shifts. Over recent years, transitions such as Shift towards Targeted Therapies and Increasing Adoption of Personalized Medicine have redefined priorities across the Pharmaceutical sector, influencing how the Pacritinib market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift towards Targeted Therapies

The pharmaceuticalindustry'sshift towards targeted therapies is significantly influencing the market performance of drugs such as Pacritinib. This new direction involves creating medications that target cellular processes linked to diseases directly. Pacritinib is an example as an oral tyrosine kinase inhibitor known for its actions, against both JAK2 and FLT3. These unique capabilities position Pacritinib well in the changing landscape of healthcare. With its ability to meet unaddressed needs in treating myelofibrosis and other blood related cancers Pacritinib demonstrates its relevance during this transformative period. Its increased market presence has not only enhanced but also spurred pharmaceutical companies to work together on the development and distribution of Pacritinib. This industry transition is expected to add $115 million in the industry revenue between 2024 and 2030.
02

Increasing Adoption of Personalized Medicine

Personalized medicine is gaining momentum, in the Pacritinib market as it focuses on tailoring treatments to each patient by taking into account individual genetic mutations through genomics and molecular diagnostics.

Related Reports

Loading related reports...